MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Archives & Legacy
*Developments: Gilead (Archives 2019-2022)
Parents
*Developments: Gilead
Archives & Legacy
Organization & Developments: Gilead
Children
2019: 8 programs to watch in NASH: Four letters and a multibillion-dollar opportunity
2019: As The Street Sours On Gilead, The Stock Looks Sweeter_seekingalpha.com
2019: Behind Gilead's Big Move On Galapagos_seekingalpha.com
2019: Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short_seekingalpha.com
2019: Faced by R&D setbacks and questionable gains, Gilead’s new CEO’s first move is to reach for the ax – Endpoints News
2019: Gilead rocked by phase 3 failure of selonsertib in NASH
2019: Gilead Sciences: Top Biotech Pick For The Next Decade With An Options Play - Gilead Sciences, Inc. (NASDAQ:GILD)
2019: Gilead takes aim at diabetic kidney disease with $109M Goldfinch deal
2019: Gilead: What A Difference An O'Day Can Make_seekingalpha.com
2019: Unsuccessful in licensing talks, feds sue Gilead over PrEP-focused HIV patent
2019: Why Gilead Could Be A Strong Outperformer Over The Coming Years_seekingalpha.com
2020: After Gilead Science's Year Of Acquisitions, 2021 Is When It Becomes An Oncology Powerhouse
2020: Antivirals Rather Than Vaccines For COVID-19
2020: AstraZeneca Approaches Gilead About Potential Merger_Bloomberg
2020: Bye Bye Remdesivir, Hello Gilead Sciences
2020: DoctoRx: Gilead: Strategic Update - Focus On 'Defend/Extend' HIV Franchise
2020: FDA anoints Gilead's remdesivir as the Covid-19 treatment winner, handing down full approval
2020: Gilead — Pivotal Covid-19 study of remdesivir ‘met its primary endpoint,' is emergency authorization next?
2020: Gilead Finally Delivers On Remdesivir
2020: Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact
2020: Gilead Inks Manufacturing Deals to Make COVID-19 Drug Remdesivir Available in 127 Countries
2020: Gilead kicks off clinical trial of inhaled remdesivir for less-severe COVID-19
2020: Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
2020: Gilead Reports (Part 1): Focus On Remdesivir For COVID-19
2020: Gilead Sciences - The Overall Portfolio Has Never Been This Strong
2020: Gilead Sciences Has The Potential To Drive Long-Term Shareholder Rewards
2020: Gilead Withdraws Request for Special Orphan Status on Experimental Virus Treatment_www.nytimes.com
2020: Gilead, Morehouse track health inequities in communities of color using COVID-19 data
2020: Gilead: 2 Upcoming Catalysts
2020: Gilead: The Growth Value Divide
2020: Gilead's Remdesivir Sold Out Already
2020: The New Gilead Is Shaping Up_seekingalpha.com
2020: UPDATED: Gilead opts for $3,120 US insurer price for Covid-19 drug remdesivir
2020: Why Gilead's COVID Drug May Be The Magic Bullet We Need
2021: Gilead and Gritstone Ink $785 Million+ Deal to Develop HIV Cure
2021: Gilead: Outperformance From Defense And Inflation Protection
2021: Gilead: Spinning Its Wheels, Despite A Beat-And-Raise Quarter
2021: Late-stage data indicates Gilead's remdesivir could be used in earlier stages of COVID
2022: A Dive Into Gilead Sciences' New HIV Medication_seekingalpha.com
2022: Gilead Reeling: Growth Assets On Hold_seekingalpha.com
2022: Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters_fiercepharma
2022: Gilead Sciences: Don't Miss The Transformation_seekingalpha.com
2022: Gilead's Quality And Growth Potential Are Underappreciated_ seekingalpha
2022: Peak Gilead_seekingalpha.com